- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie, Omontys (peginesatide) / Affymax, Krystexxa (pegloticase) / Horizon Therapeutics
ROS-scavenging (Regency Ballroom C (Hyatt Regency Indianapolis)) - Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_12755;
B. Unlike with PEG, no anti-polymer antibodies were formed in PTGG/OVA treated mice.
- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie
Journal: Nucleic acid therapeutics: A focus on the development of aptamers. (Pubmed Central) - Oct 8, 2021
Surprisingly, and promisingly, the ability of nucleic acid therapeutics to breach the blood brain barrier seems achievable. The recognition of specific motifs, e.g. G-quadruplex in thrombin-binding aptamers, or a 'nucleation' zone while designing aptamer-antidote pairs, is likely to accelerate the discovery of therapeutically efficacious molecules.
- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie
Review, Journal: Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? (Pubmed Central) - Oct 10, 2020
Overall, the risk of developing a g-NET appears greatest in patients who are more than 10 years on drug and on higher doses: those affected by chronic H. pylori gastritis and/or consequent gastric atrophy may also be at increased risk. While the overall risk of g-NETs induced by PPI therapy is undoubtedly low, it is real: this necessitates caution in using PPI therapy for long periods of time, particularly when initiated in young subjects.
- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie
Biomarker, Clinical, Journal: Non-immunological biomarkers for assessment of villous abnormalities in patients with celiac disease. (Pubmed Central) - Sep 16, 2020
While the overall risk of g-NETs induced by PPI therapy is undoubtedly low, it is real: this necessitates caution in using PPI therapy for long periods of time, particularly when initiated in young subjects. Plasma citrulline ≤ 30 μM/L is the most consistent, highly reproducible non-invasive biomarker that can predict the presence of villous abnormality and has the potential for avoiding duodenal biopsies in 78% patients suspected to have CeD.
- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie
Journal: Fine-Tuning of Energy Levels Regulates SUC2 via a SNF1-Dependent Feedback Loop. (Pubmed Central) - Sep 16, 2020
Our systems biology approach proposes a negative feedback mechanism that works through the SNF1 complex and is controlled by energy levels. We further show that Reg1 likely is involved in the negative feedback mechanism.
- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie
Journal: Reg-1α Promotes Differentiation of Cortical Progenitors via Its N-Terminal Active Domain. (Pubmed Central) - Sep 10, 2020
Notably, the N-terminal soluble domain, but not the C-type lectin domain, is largely responsible for Reg-1α effects on cortical neuronal differentiation. We thus conclude that Reg-1α via its proteolytically generated N-terminal domain is required for basic development processes.
- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie
Journal: Spontaneous mutations that confer resistance to 2-deoxyglucose act through Hxk2 and Snf1 pathways to regulate gene expression and HXT endocytosis. (Pubmed Central) - Sep 9, 2020
Missense alleles of the HXK2, REG1, GLC7 and SNF1 genes were shown to confer significant resistance to 2-deoxyglucose and all had the potential to alter the activity and or target selection of the Snf1 kinase signaling pathway...These findings suggest the common adaptive response to 2DG is to limit the magnitude of the response. Genetic studies of 2DG resistance using the dominant SNF1-G53R allele in cells that are genetically compromised in both the endocytosis and DOG pathways suggest that at least one more mechanism for conferring resistance to this glucose analog remains to be discovered.
- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie
REG01 Satellite Registration (Hyatt Regency Seattle, 3rd Floor Foyer) - Jun 20, 2020 - Abstract #ACOG2020ACOG_332;
- |||||||||| anivamersen/pegnivacogin (RB 006/RB 007) / Allergan
Journal: Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. (Pubmed Central) - Mar 14, 2020
Moreover, in parallel studies we detected the presence of anti-PEG antibodies in nonhuman primates after a single administration of a PEGylated aptamer. Our results suggest that anti-PEG antibodies can limit the activity of PEGylated drugs and potentially compromise the activity of otherwise effective therapeutic agents.
- |||||||||| anivamersen/pegnivacogin (RB 006/RB 007) / Allergan
Journal: To PEGylate or Not To PEGylate Therapeutics? (Pubmed Central) - Feb 14, 2020
In this issue of Cell Chemical Biology, Moreno et al. (2019) show anti-PEG antibodies may directly inhibit the activity of a PEGylated aptamer, RB006, both in vitro and in vivo, and the issues surrounding anti-PEG antibodies are discussed.
- |||||||||| Revolixys (anivamersen/pegnivacogin) / AbbVie
Enrollment change, Trial termination, Trial primary completion date: A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (clinicaltrials.gov) - Oct 23, 2014
P3, N=3232, Terminated,
(2019) show anti-PEG antibodies may directly inhibit the activity of a PEGylated aptamer, RB006, both in vitro and in vivo, and the issues surrounding anti-PEG antibodies are discussed. N=13200 --> 3232 | Suspended --> Terminated | Trial primary completion date: Sep 2015 --> Aug 2014; Clinical Hold
|
